99m Tc-ANNexin-V-128 Scintigraphy for the Identification of Complicated Carotid Atherosclerotic Plaques (ANNICA)


Assistance Publique - Hôpitaux de Paris

Status and phase

Phase 3
Phase 2


Carotid Atherosclerosis
Atherosclerotic Plaque


Other: 99mTc-Annexin-V-128 uptake on scintigraphy

Study type


Funder types



2017-002952-99 (EudraCT Number)

Details and patient eligibility


The aim of this trial will be to test and validate the value of scintigraphy with injection of 99mTc-Annexin-V-128 for the detection of complicated carotid plaques

Full description

Introduction Stroke represents the third cause of death, the first cause of handicap and the second cause of dementia in Europe. Carotid atherosclerotic plaques are the cause of ischemic stroke in about 15 to 20 % of the patients. In presence of carotid stenosis > 50 %, the risk of ischemic stroke is estimated at about 10% per year when the patient has presented symptoms of cerebral ischemia but only at 2% per year in asymptomatic patients. Clinical benefits of surgical carotid endarterectomy have been demonstrated in symptomatic patients with high degree of carotid stenosis, but remain debatable in asymptomatic patients and should be balanced with the risks associated with the revascularization procedure. There is an urgent need to develop imaging tools that improve the identification of patients at highest risk of developing an ischemic stroke Cellular apoptosis is a key feature of ruptured plaques. Apoptotic macrophages release large amounts of tissue factor within the plaque thereby fostering thrombus formation when plaques rupture. Annexin-V is a 36-kDa protein that binds with high affinity and high specificity to phosphatidylserine (PS) head groups expressed on the cell surface at early stages of the apoptotic process. In addition, activated platelets express large amounts of PS at their surface. In a proof-of-concept study, 99mTc-Annexin-V uptake was detected by scintigraphy in carotid atherosclerotic plaques of 4 patients who presented an acute ischemic stroke and was associated with the presence of apoptotic cells on corresponding carotid plaques obtained after carotid endarterectomy procedure. Design : Monocentric interventional non comparative study Investigational medicinal product(s): 99mTc-Annexin-V-128 Statistical procedure : Statistical analysis will be performed at the end of the study after blinded review and data freezing. 99mTc-Annexin-V-128 uptake will be analyzed as a binary variable considering the presence or absence of detection and as a quantitative variable for the intensity of signal.




18 to 90 years old


No Healthy Volunteers

Inclusion criteria

  • 18 years ≤ Age ≤ 90 years
  • Patients with clinical indications to carotid endarterectomy
  • Signed the consent form.
  • Affiliation of a social security regime

Exclusion criteria

  • Non-menopausal women
  • Chronic kidney disease (eGFR < 45 ml/min/1.73 m2)
  • Waldenstrom disease
  • Multiple myeloma
  • Previous severe adverse reaction to iodinated contrast agent
  • Impossibility to stay immobile and maintain the supine position during 20 minutes.
  • Altered consciousness or inability to understand the consent form.
  • Urinary incontinence without implantation of urinary catheter (risk of urinary contamination).
  • Non-atherosclerotic carotid stenosis (history of cervical radiation).
  • Patient deprived of liberty or under legal protection measure

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

0 participants in 1 patient group

99mTc-Annexin-V-128 uptake on scintigraphy
Experimental group
Other: 99mTc-Annexin-V-128 uptake on scintigraphy

Trial contacts and locations



Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems